REGULATORY

• Council OKs Public Knowledge-Based Submissions for New Azathioprine, Temozolomide Indications
  July 5, 2018

• Govt Likely to Allow 600 Billion Yen Rise for FY2019 Social Security Budget Request
  July 4, 2018

• Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
  July 4, 2018

• LDP Lawmakers Launch New Study Group on Life Science Industry
  July 3, 2018

• MHLW OKs 1st Pfizer Biosimilar, Add’l Indications and Dosages
  July 3, 2018

• MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
  July 3, 2018

• PMDA Reveals First 2 Cases of MID-NET Regulatory Use
  July 2, 2018

• LDP’s Patch Panel Boots Up with Bigwig Noda as Chairman
  June 28, 2018

• MHLW to Remove Pregnancy Contraindication for 3 Immunosuppressants
  June 27, 2018

• Ryukaikon Working Group to Discuss Rebates Offered to Make Up for Higher Invoice Prices
  June 26, 2018

• New LDP Study Group to Kick Off with Focus on Innovation in Life Science
  June 25, 2018

• PMDA Wants to Increase Safety Staffers to 270 by FY2023: Official
  June 21, 2018

• Public Insurance Should Cover Pricy Drugs, Rather than Cold Medicines: MHLW’s Top MD Bureaucrat
  June 21, 2018

• PMDA Slips to Second in Time-to-Approval Ranking
  June 21, 2018

• LDP’s Pharma Study Group to Form Panel for Patch Medications, Proposal Due Out This Autumn
  June 20, 2018

• PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
  June 19, 2018

• Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing
  June 18, 2018

• Authorized Generics for Aimix, Cravit IV Join NHI Price List
  June 15, 2018

• Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
  June 14, 2018

• Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
  June 14, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 215
• 216
• 217
• 218
• 219
• 220
• 221
• 222
• 223
• …
• Next ›
• 最終 »